Citations

Clear

4 citation(s) found for "Pellini, Bruna".

Early ctDNA Stratifies Survival in Locally Advanced and Oligometastatic Lung Cancer Treated with Radiotherapy
Hashmi, Ayesha , Linford, Jessica , Chauhan, Pradeep S, Parikh, K, Pillai, Malvika , Guittar, John , Ben-Shachar, Rotem , Patel, Jyoti , Nimeiri, Halla , Bergsagel, Matteo , Park, S, Olivier, Kenneth R. , Owen, Dawn , Lee, K.N. , Morgensztern, Daniel, Robinson, Clifford G, Bergom, Carmen , Samson, Pamela , Pellini, B., Vlacich, Gregory , Chaudhuri, Aadel A, Chauhan, Pradeep S. , Ben‐Shachar, Rotem , Chauhan, Pradeep S , Parikh, Kaushal , Patel, Jyoti , Semenkovich, Nicholas P , Park, Sean S , Owen, Dawn , Routman, David M , Lee, Katie N , Sherry, Alexander D , Mansfield, Aaron S , Morgensztern, Daniel , Govindan, Ramaswamy , Robinson, Clifford , Bergom, Carmen , Waqar, Saiama N , Samson, Pamela P , Pellini, Bruna , Vlacich, Gregory R , Chaudhuri, Aadel A , Patel, Jyoti D. , Semenkovich, Nicholas P. , Routman, David M. , Sherry, Alexander D. , Mansfield, Aaron S. , Morgensztern, Daniel , Govindan, Ramaswamy , Pellini, Bruna , Chaudhuri, Aadel A.

Mayo Clinic

Clinical Cancer Research | April 30, 2026 | Volume: 32 | Issue: 14 | Pages: 2945-2956

10.1158/1078-0432.ccr-25-4983 | PMID 42059900 Get It

Abstract Purpose: Circulating tumor fraction estimate (ctFE) is a machine learning–derived composite metric of circulating tumor DNA (ctDNA) burden. We hypothesized that pre-treatment and early on-treatment ctFE could robustly risk-stratify patients with locally advanced (LA) and oligometastatic non–small cell lung cancer (NSCLC) treated with radiotherapy (RT). Experimental Design: In a prospective phase II clinical trial (NCT03916419), 26 patients with unresectable stage IIB to IIIC NSCLC received magnetic resonance (MR)-guided hypofractionated chemoradiotherapy (chemoRT) followed by immunotherapy. Plasma ctDNA was profiled at baseline and mid-treatment (days 10–14) to derive ctFE and maximum variant allele frequency (Max VAF). A burden-based ctFE threshold derived from baseline samples was applied unchanged to mid-treatment samples and validated in two external cohorts: LA NSCLC treated with chemoRT (LA-RW; n = 94) and oligometastatic NSCLC treated with RT (OM-RW; n = 309). Results: Pre- and mid-treatment ctFE burden strongly stratified overall survival (OS) and progression-free survival (PFS), outperforming Max VAF and ctFE detectability. The baseline ctFE was prognostic for OS (HR 5.93, P = 0.005) and PFS (HR 11.08, P < 0.001) and remained significant at mid-treatment (OS: HR 7.08; PFS: HR 12.06; both P < 0.001). Early ctFE dynamics defined three molecular response groups with OS separation (median OS 60.8 vs. 13.0 vs. 2.9 months; P < 0.001). ctFE remained associated with survival in both validation cohorts. Conclusions: Early ctFE derived from a clinically available, tumor-naïve ctDNA assay enables noninvasive risk stratification in LA and oligometastatic NSCLC treated with RT, supporting its use as a practical biomarker for precision treatment adaptation.
Abstract 1183: Early ctDNA quantification by ctFE outperforms Max VAF for survival stratification across locally advanced and oligometastatic NSCLC treated with radiotherapy.
Hashmi, Ayesha , Linford, Jessica , Parikh, K., Ben-Shachar, Rotem, Guittar, John , Pillai, Malvika , Patel, Jyoti D., Bergsagel, Matteo , Olivier, K., Park, Sean S., Owen, Dawn, Lee, K.N. , Sherry, Alex, Morgensztern, Daniel , Ferreira, Bruna Pellini, Vlacich, Gregory , Chaudhuri., Aadel A., Chauhan, Pradeep S. , Ben‐Shachar, Rotem , Semenkovich, Nicholas P. , Routman, David M. , Mansfield, Aaron S. , Govindan, Ramaswamy , Robinson, Clifford G. , Bergom, Carmen , Waqar, Saiama N , Chaudhuri, Aadel A.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 1183-1183

10.1158/1538-7445.am2026-1183 Get It

Abstract Background: Personalizing chemoradiotherapy (chemoRT) for locally advanced non-small cell lung cancer (LA-NSCLC) is limited by the lack of early biomarkers that inform response during treatment. Current circulating tumor DNA (ctDNA) molecular residual disease assays predict post-treatment outcomes but lack mid-treatment utility. ctDNA burden estimation has traditionally relied on variant-centric metrics such as maximum variant allele fraction (Max VAF), which rely on mutation-specific signals and may be confounded by histology-dependent shedding variability, allelic imbalance, and clonal hematopoiesis. Here we present circulating tumor fraction estimate (ctFE), a machine-learning composite score that integrates VAF distributions, copy-number alterations, and germline B-allele frequency deviations to approximate global tumor burden using a widely available, tumor-naïve clinical platform. Methods: A burden-based ctFE threshold was derived using pre-treatment plasma from a prospective phase II clinical trial of MR-guided hypofractionated chemoRT (LA-WU, n=26), locked, and applied unchanged to early mid-treatment samples (day 10-14). To test scalability and generalizability, its prognostic performance was validated in two real-world cohorts: 94 LA-NSCLC patients receiving definitive chemoRT (LA-RW) and 309 oligometastatic NSCLC patients receiving consolidative RT (OM-RW). ctFE and Max VAF were compared as continuous predictors across cohorts. Results: ctFE consistently outperformed Max VAF. In LA-WU, pre-treatment ctFE was associated with overall survival (OS HR=1.15, p=0.04) and progression-free survival (PFS HR=1.84, p=0.009), whereas Max VAF was not. Mid-treatment ctFE remained prognostic for PFS (HR=1.14, p=0.026). Early ctFE dynamics defined three molecular response groups with marked OS separation: consistently low, responder, and nonresponder groups (median OS 60.8 vs 13.0 vs 2.9 months, respectively; p<0.001). In multivariable models including both biomarkers, higher ctFE remained independently associated with worse survival in LA-RW (OS HR=1.88, p=0.010) and OM-RW (OS HR=1.37, p=0.040; PFS HR=1.45, p=0.008), whereas Max VAF did not. The locked ctFE threshold stratified OS across all cohorts (LA-WU HR=5.93; LA-RW HR=9.08; OM-RW HR=2.26; all p<0.001). Conclusion: ctFE provides clinically meaningful pre- and mid-treatment risk stratification and consistently outperforms Max VAF across locally advanced and oligometastatic NSCLC cohorts. We show that ctFE is a biologically informative, clinically generalizable and scalable ctDNA burden metric measurable using a tumor-naïve, off-the-shelf assay, supporting its practical utility in biomarker-adapted radiotherapy strategies. Citation Format: Ayesha Hashmi, Jessica Linford, Pradeep S. Chauhan, Kaushal Parikh, Rotem Ben-Shachar, John Guittar, Malvika Pillai, Jyoti Patel, Matteo Bergsagel, Nicholas P. Semenkovich, Kenneth R. Olivier, Sean S. Park, Dawn Owen, David M. Routman, Katie N. Lee, Alex D. Sherry, Aaron S. Mansfield, Daniel Morgensztern, Ramaswamy Govindan, Clifford G. Robinson, Carmen Bergom, Saiama N. Waqar, Bruna Pellini Ferreira, Gregory R. Vlacich, Aadel A. Chaudhuri. Early ctDNA quantification by ctFE outperforms Max VAF for survival stratification across locally advanced and oligometastatic NSCLC treated with radiotherapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 1183.
Racial Disparities in Early-Stage NSCLC Treatment: A Call for Action
Pellini, Bruna , Chaudhuri, Aadel A. , Pellini, Bruna

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | April 8, 2024 | Volume: 33 | Issue: 6 | Pages: 769-770

10.1158/1055-9965.epi-24-0339 | PMID 38587480 Get It

Abstract Non–small cell lung cancer (NSCLC) is associated with a 5-year survival rate of only 28%; however, when caught at an early stage, it can be cured with surgery or stereotactic body radiotherapy (SBRT). Unfortunately, racial disparities may result in limited access to care for some patients. Liu and colleagues analyzed 64,999 cases of early-stage NSCLC treated between 2005 and 2017 from the Florida Cancer Registry and showed that Black patients had 36% lower odds of receiving curative-intent surgery compared with their White counterparts. This study highlights significant racial disparities in treatment patterns that must be addressed urgently. See related article by Liu and colleagues, Cancer Epidemiol Biomarkers Prev 2024;33:489–99
Treatment Strategies for Non-Small Cell Lung Cancer with Common EGFR Mutations: A Review of the History of EGFR TKIs Approval and Emerging Data
Marin‐Acevedo, Julian A. , Pellini, Bruna , Kimbrough, ErinMarie O. , Hicks, J. Kevin , Hicks, J Kevin , Pellini, Bruna , Chiappori, Alberto

Mayo Clinic

Cancers | January 19, 2023 | Volume: 15 | Issue: 3 | Pages: 629

10.3390/cancers15030629 | PMID 36765587 Get It

The development of targeted therapies over the past two decades has led to a dramatic change in the management of EGFR-mutant non-small cell lung cancer (NSCLC). While there are currently five approved EGFR tyrosine kinase inhibitors (TKIs) for treating EGFR-mutant NSCLC in the first-line setting, therapy selection after progression on EGFR TKIs remains complex. Multiple groups are investigating novel therapies and drug combinations to determine the optimal therapy and treatment sequence for these patients. In this review, we summarize the landmark trials and history of the approval of EGFR TKIs, their efficacy and tolerability, and the role of these therapies in patients with central nervous system metastasis. We also briefly discuss the mechanisms of resistance to EGFR TKIs, ongoing attempts to overcome resistance and improve outcomes, and finalize by offering treatment sequencing recommendations.